ITRMF (Iterum Therapeutics) General and Admin. Expense: $15.57 Mil (TTM As of Sep. 2025)


What is Iterum Therapeutics General and Admin. Expense?

Iterum Therapeutics ITRMF +18.86% General and Admin. Expense is $15.57 Mil as of Sep. 2025. The stock has 4 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Iterum Therapeutics's General and Admin. Expense for the three months ended in Sep. 2025 was $6.49 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Sep. 2025 was $15.57 Mil.

Iterum Therapeutics General and Admin. Expense Related Terms

Iterum Therapeutics General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for Iterum Therapeutics's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Iterum Therapeutics General and Admin. Expense Chart

Iterum Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only 11.05 13.83 12.77 7.48 7.98

Iterum Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.78 2.12 2.78 4.18 6.49

Iterum Therapeutics General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $15.57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of $15.57 Mil mean?
Iterum Therapeutics (ITRMF) has a General and Admin. Expense of $15.57 Mil as of Sep. 2025. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Iterum Therapeutics and its competitors.
Is Iterum Therapeutics' General and Admin. Expense too high?
Iterum Therapeutics' current General and Admin. Expense is $15.57 Mil.
How does Iterum Therapeutics' General and Admin. Expense compare to ENSC and PPCB?
Iterum Therapeutics' General and Admin. Expense of $15.57 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Iterum Therapeutics and its competitors. Iterum Therapeutics's current General and Admin. Expense is $15.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iterum Therapeutics stock overvalued right now?
Iterum Therapeutics (ITRMF) has a current General and Admin. Expense of $15.57 Mil. The current General and Admin. Expense is $15.57 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For Iterum Therapeutics (ITRMF), the current General and Admin. Expense is $15.57 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Iterum Therapeutics Business Description

Address 3 Dublin Landings, North Wall Quay, Dublin 1, Dublin, IRL, D01 C4E0
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.